In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

According to the paper by researchers at the University of Bath in the UK and Lund University in Sweden, the self-regulated ...

Bioanalysis is also used to monitor therapeutic responses by evaluating drug levels, biomarkers, and physiological changes ...

In conclusion, I see 2025 as a year in which the patient will still be centre-stage. But, in order for that to happen ...

The stake comes alongside an agreement for Vancouver, Washington-based Absci to use AMD chips and software to power its drug ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...